Overview

A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)

Status:
Recruiting
Trial end date:
2022-12-20
Target enrollment:
Participant gender:
Summary
This is a prospective, multicenter, open-label, randomized, controlled, parallel group, group-sequential, event-driven Phase 3 study to evaluate efficacy, safety and pharmacokinetics (PK) of macitentan in children.
Phase:
Phase 3
Details
Lead Sponsor:
Actelion
Treatments:
Macitentan